Inovio Pharmaceuticals (US:INO) — Company Overview, News & Financial Data

Inovio Pharmaceuticals logo
INOInovio Pharmaceuticals
Trade INO now
Inovio Pharmaceuticals primary media

About Inovio Pharmaceuticals

Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology firm focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines for infectious diseases and cancer. The company leverages its proprietary plasmid DNA technology to stimulate robust and specific immune responses. Inovio's pipeline includes candidates for HPV-associated diseases, cancer, and infectious diseases such as COVID-19. With a commitment to global health, Inovio aims to innovate and make accessible new vaccines and therapies that can change the course of human diseases. Additionally, the company collaborates with industry leaders and organizations worldwide to advance and expand its reach in public health.

What is INO known for?

Snapshot

Public US
Ownership
1999
Year founded
262
Employees
Plymouth Meeting, United States
Head office
Loading Map...

Operations

All Locations
United States

Products and/or services of Inovio Pharmaceuticals

  • INO-4800, a DNA vaccine candidate for COVID-19, designed to precisely target the SARS-CoV-2 virus.
  • VGX-3100, a DNA-based immunotherapy for the treatment of HPV-related precancers.
  • Cellectra, a proprietary smart device for delivering DNA vaccines and therapeutics directly into the skin.
  • INO-5401, a combination therapy targeting glioblastoma, a lethal brain cancer, using multiple immunotherapeutic agents.
  • INO-5151, a DNA-based therapy aimed at treating prostate cancer by targeting specific cancer antigens.
  • DNA medicines platform, providing rapid development of vaccines and therapies for infectious diseases and cancer.

Inovio Pharmaceuticals executive team

  • Dr. Jacqueline E. Shea Ph.D.CEO, President & Director
  • Mr. Peter D. KiesChief Financial Officer
  • Dr. Michael Sumner B.S., M.B.A., M.D.Chief Medical Officer & Head of Development
  • Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer & Chairman of the Scientific Advisory Board
  • Thomas HongManager of Investor Relations
  • Mr. Robert L. Crotty J.D.General Counsel, Corporate Secretary & Chief Compliance Officer
  • Mr. E. J. Brandreth MBASenior Vice President of Quality Assurance
  • Dr. Jeffrey SkolnikSenior Vice President of Clinical Development
  • Mr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
  • Mr. Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.